Online Program Home
My Program

Abstract Details

Activity Number: 464 - SPEED: Infectious Diseases, Spatial Modeling and Environmental Exposures, Speed 1
Type: Contributed
Date/Time: Wednesday, July 31, 2019 : 8:30 AM to 10:20 AM
Sponsor: Section on Statistics in Epidemiology
Abstract #301760
Title: Zoster Vaccine Live Coverage Among Adults 50-59 and ?60 Years in the United States, 2013-2017
Author(s): Pengjun Lu* and Mei-Chuan Hung and Anup Srivastav and Walter W Williams and Kathleen Dooling
Companies: CDC and CDC and Centers for Disease Control and Prevention/Leidos Inc and Centers for Disease Control and Prevention and CDC
Keywords: Shingles vaccine; vaccination; coverage; adult; herpes zoster

The live zoster, or shingles, vaccine (ZVL) has been recommended by the Advisory Committee on Immunization Practices (ACIP) for adults aged >60 years since 2006. ZVL is licensed but not recommended by the ACIP for adults aged 50-59 years. In October 2017, ACIP recommended recombinant zoster vaccine (RZV) for adults aged ?50 years. This study assessed ZVL coverage among adults aged ?60 years and 50-59 years before RZV was widely available. Data from the 2013-17 National Health Interview Survey (NHIS) were analyzed. In 2017, 34.9% of adults aged ?60 years reported shingles vaccination, an increase of 10.7 percentage points from 24.2% in 2013 (test for trend, p< 0.05). In 2017, coverage among adults aged ?60 years was lower among non-Hispanic blacks (17.1%), Hispanics (19.9%), and Asians (31.9%) compared with non-Hispanic whites (39.3%). Among adults aged 50-59 years, ZVL vaccination coverage was 5.7% in 2017 and coverage did not increase during 2013-2017 (test for trend, p>0.05). These findings provide a baseline for assessing introduction of RZV vaccine using future NHIS data. Increased efforts using comprehensive strategies are needed to improve shingles vaccination coverage.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2019 program